Abstract
The objective of this study was to report the effect of the slow withdrawal of clozapine from 19 patients withneuroleptic-responsive schizophrenia at the end of a 2-year clinical trial of clozapine and to compare this with the results of naturalistic discontinuation of clozapine treatment in 64neuroleptic-resistant schizophrenic patients. Nineteen neuroleptic-responsive schizophrenic patients who received clozapine were withdrawn from clozapine by tapering it over 3-week period with and without the addition of a typical neuroleptic. Fifteen of the 19 neuroleptic-responsive patients experienced the return of psychotic symptoms during or after the clozapine taper, which were most severe in the ten patients in whom the withdrawal of clozapine was carried out without prior addition of neuroleptic treatment. Addition of a neuroleptic prior to clozapine withdrawal prevented the emergence of positive symptoms during clozapine withdrawal in each of eight patients. Nevertheless, psychotic symptoms emerged, usually within a week after discontinuing clozapine, in six of the eight patients. Neuroleptic treatment, with or without an anticholingergic drug, was much less effective in treating positive symptoms in these patients immediately after the clozapine withdrawal than it had been 2 years previously. Cyproheptadine, a non-selective serotonin receptor antagonist, augmented the antipsychotic effect of neuroleptics in each of four patients who relapsed following withdrawal from clozapine and relieved extrapyramidal symptoms in a fifth patient. The frequency of relapse following withdrawal of clozapine in 64 neuroleptic-resistant patients was significantly lower (25/64, 39.1%) than in the neuroleptic-responsive patients.
Similar content being viewed by others
References
Alphs LD, Lee HS (1991) Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 52:346–348
Bacher NM, Sanzone MM, Kamp B (1994) Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine. J Clin Psychopharmacol 14:424–425
Borison RL, Diamond BI, Sinha D, Gupta RP, Ajboye PA (1988) Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24:260–263
Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20–26
Buckland PR, O'Donovan MC, McGriffin P (1992) Changes in dopamine D1, D2, and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology 106:479–483
Buckland PR, O'Donovan MC, McGriffin P (1993) Clozapine and sulpiride up-regulate dopamine D3 receptormRNA levels. Neuropharmacology 32:901–907
Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25–40
Davis KL, Rosenberg GS (1979) Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 14:699–703
Diamond BI, Borison RL (1986) Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull 26:900–905
Dickson R, Williams R, Dalby JT (1994) Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 39:184
Ekblom B, Haggstrom JE (1974) Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 16:945–957
Ekblom B, Eriksson K, Lindström LH (1984) Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 83:293–294
Eklund K (1987) Supersensitivity and clozapine withdrawal. Psychopharmacology 91:135
Endicott J, Spitzer RL (1978) A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35:837–844
Fink H, Morgenstern R, Oelssner W (1979) Psychotomimetics potentiate locomotor hyperactivity induced by dopaminergic drugs. Pharmacol Biochem Behav 11:479–482
Fischer-Cornelssen KA, Ferner UJ, Steiner H (1974) Multifokale Psychopharmaka-prufung (“Multihospital Trial”). Arzneimittelforschung 24:1706–1724
Garrison JC (1990) Histamine, bradykinesia, 5-hydroxytryptamine, and their antagonists. In Gelenberg AJ, Doller JC (1979) Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry 40:238–240
Gerlach J, Koppelhus P, Helweg E, Manrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial. Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410–424
Gilbert PL, Harris WJ, McAdams LA, Jeste DA (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 52:173–188
Glovinsky D, Kirch DG, Wyatt RJ (1992) Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry 31:968–970
Halperin R, Guerin JJ Jr, Davis KL (1989) Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology 98:386–391
Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993) Relationship between clinical efficacy and clozapine plasma concentrations in schizophrenia: effect of smoking. J ClinPsychopharmacol 13:383–390
Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10[3]:388–398
Hogarty G, Ulrich R, Mussare F, Aristigueta N (1976) Drug discrimination among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst 37:494–500
Ichikawa J, Meltzer HY (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J Pharmacol Exp Ther 256:348–357
Ichikawa J, Meltzer HY (1995) DOI, a 5-HT2C/2A receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res (in press)
Ichikawa J, Meltzer HY (1992) Amperozide, a novel antipsychotic drug, inhibits the ability ofd-amphetamine to increase dopamine release in vitro in rat striatum and nucleus accumbens. J Neurochem 58:2285–2291
Idzikowski C, Cowen PJ, Mutt D, Mills FJ (1987) The effects of chronic ritanserin treatment on sleep and the neuroendocrine response toL-tryptophan. Psychopharmacology 93:416–420
Idzikowski C, Mills FJ, James RJ (1991) A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharmacol 31:193–196
Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796
Krupp P, Barnes P (1989) Leponex®-associated granulocytopenia: a review of the situation. Psychopharmacology (Suppl) 99:S118-S121
Kuoppamäki M, Seppälä T, Syvälahti E, Hietala J (1993) Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264:1262–1267
Lee MA, Thompson P, Meltzer HY (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55[Suppl B]:82–87
Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ (1995) Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol 10:67–72
Linszen DH, Dinegemans PM, Lenoir ME, Nugter MA, Scholte WF, Van der Does AJW (1994) Relapse criteria in schizophrenic disorders: difference perspectives. Psychiatry Res 54:273–281
Llorca DM, Wolf MA, Laneon C, Bougerol T (1993) Efficcaté compareé de la bromocriptine, de la carbamazépine et de la cyproheptadine, schizophrènes chroniques résistants. Encephale 19:565–571
Luchins DJ, Freed WJ, Wyatt RJ (1980) The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 137:1395–1398
Matsubara S, Meltzer HY (1989) Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 45:1397–1406
Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263–287
Meltzer HY (1992a) Dimensions of outcome with clozapine. Br J Psychiatry 160 [Suppl 17]:46–53
Meltzer HY (1992b) Treatment of the neuroleptic non-responsive schizophrenic patients. Schizophr Bull 18:515–542
Miller DD, Flaum M, Arndt S, Fleming F, Andreasan NC (1994) Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 11:11–20
Miller RJ, Hiley CR (1974) Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248:596–597
Nash JF, Meltzer HY, Gudelsky GA (1990) Effect of 3,4-methylenedioxymethamphetamine on 3,4-di-hydroxyphenylalanine in the striatum and nucleus accumulation in the striatum and nucleus accumbens. J Neurochem 54:1062–1067
Neylan TC, Van Kammen DP, Kelley ME, Peters JL (1992) Sleep in schizophrenic patients on and off haloperidol therapy: clinically stable versus relapsed patients. Arch Gen Psychiatry 49:643–649
Overall JE, Gorham D (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:149–165
Parsa MA, Al-Lanhram Y, Ramirez LF, Meltzer HY (1993) Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 13:154–155
Perényi A, Kunsz E, Bagdy G (1985) Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology 86:244
Perry PJ, Miller DD, Arndt S, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231–235
Prien RF, Cole J, Belkin N (1968) Relapse in chronic schizophrenics following abrupt withdrawal of tranquilizing medication. Br J Psychiatry 115:679–686
Rupniak NMJ, Kilpatrick G, Hall MD, Jenner P, Marsden CD (1984) Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology 84:512–519
Schremmer C, Morgenstern R, Fink H, Oh T (1990) Atypical neurlopetics suppress dopaminergic behavioral supersensitivity. Psychopharmacology 100:399–403
Sharpley AL, Solomon RA, Fernando AI, da Roza Davis JM, Cown PJ (1990) Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 101:568–569
Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, Kurtz NM, Cutler NR (1995) Cholinergic rebound and rapid onset psychosis following abrupt clozapine with-drawal. Schizophr Bull (in press)
Shopsin B, Klein H, Aaronson M, Collora M (1979) Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients. Arch Gen Psychiatry 36:657–664
Shore D, Matthew S, Cott J, Lieberman JA (1995) Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 21:333–338
Silver H, Blacker M, Weller MP, Lerer B (1989) Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 25:502–504
Silver H, Blacker M, Weller MP, Lerer B (1991) Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo controlled study. Biol Psychiatry 30:523–525
Solomon RA, Sharpley AL, Cowen PJ (1984) Increased slow wave sleep with 5-HT2 receptor antagonists; detection by ambulatory EEG recording and automatic sleep stage analysis. J Psychopharmacol 3:125–129
Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Kettler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684–691
Specchio LM, Puca FM, Genco S, Candeliere G, Galeone D, Dammacco F (1976) Effectti della ciproheptadine sul sonno dellumo normale. Boll Soc Ital Biol Sper 52:1789–1793
Stutzmann JM, Eon B, Roux M, Lucas M, Blanchard JC, Laduron RM (1990) RP 62203, a 5-HT2 antagonist, enhances slow wave sleep in rats. 17th Congress of Collegium Internationale Neuropharmacologicum, Kyoto, Japan, Abstract 1394
Van Rizen H (1972) Different central effects of the 5-HT antagonists mianserin and cyproheptadine. Arch Int Pharmacodyn 198:256–269
Vencovsky E, Peterova E, Baudis P (1975) Comparison of therapeutic effect of clozapine and chlorpromazine. Ceskoslovenska Psychiatric 71:21–26
Wilmot CA, Szczepanick AM (1989) Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT) and dopamine (D2) receptors in the rat brain. Brain Res 487:288–298
Yamamoto BK, Pehek EA, Meltzer HY (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55 [Suppl B]:8–14
Zapletálek M, Preiningerova O, Hanus H (1980) Does clozapine cause dependence? (German) Agressologie 21[A]:19–22
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meltzer, H.Y., Lee, M.A., Ranjan, R. et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology 124, 176–187 (1996). https://doi.org/10.1007/BF02245619
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245619